Allergan Spending $10M A Month Fighting Pershing Square, Valeant

Nov 6 2014 | 10:45am ET

Fending off the unwanted attention of Pershing Square Capital Management and Valeant Pharmaceuticals International is proving expensive for Allergan Inc.

The Botox-maker said it spent more than $30 million in the third quarter battling Valeant’s hostile takeover bid, which is backed by Pershing Square as part of an unusual partnership. The spending matched Allergan’s expenses in the battle in the second quarter, meaning the company is spending about $10 million per month to stave off the $53 billion deal.

Among those advising Allergan in its fight are law firms Wachtell Lipton Rosen & Katz and Latham & Watkins, and Bank of America Merrill Lynch and Goldman Sachs. The company has also engaged proxy solicitor Innisfree, forensic accountancies FTI Consulting and Alvarez & Marshall, and public-relations firm Joele Frank.

The expense of the fight pushed Allergan’s administrative costs for the third quarter up 21%, it said yesterday.

Pershing Square’s bid to oust a majority of Allergan’s board will go before its shareholders on Dec. 18. A federal judge this week refused to block Pershing Square, Allergan’s largest shareholder, from voting its 9.7% stake, potentially clearing the way for Valeant’s takeover.

In Depth

PAAMCO: Will Inflation Deflate the Asset Bubble?

Jan 30 2018 | 9:49pm ET

As the U.S. shifts from monetary stimulus to fiscal stimulus, market pricing should...


CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Boost Hedge Fund Marketing ROI By Raising Your ROO

Feb 14 2018 | 9:57pm ET

Tasked with delivering returns on client capital, a common dilemma for many alternative...